GILD logo

GILD
Gilead Sciences, Inc.

77,732
Mkt Cap
$182.67B
Volume
6,954.00
52W High
$153.13
52W Low
$93.37
PE Ratio
22.80
GILD Fundamentals
Price
$147.23
Prev Close
$151.68
Open
$151.47
50D MA
$128.40
Beta
0.37
Avg. Volume
7.75M
EPS (Annual)
$6.78
P/B
8.49
Rev/Employee
$1.67M
$131,594.35
Loading...
Loading...
News
all
press releases
Caprock Group LLC Invests $7.23 Million in Gilead Sciences, Inc. $GILD
Caprock Group LLC bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the...
MarketBeat·3h ago
News Placeholder
More News
News Placeholder
Advisors Asset Management Inc. Reduces Stock Holdings in Gilead Sciences, Inc. $GILD
Advisors Asset Management Inc. trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 17.4% in the 3rd quarter, according to the company in its most recent Form 13F...
MarketBeat·5h ago
News Placeholder
Gilead Sciences (NASDAQ:GILD) Updates FY 2026 Earnings Guidance
Gilead Sciences (NASDAQ:GILD) updated its FY 2026 earnings guidance. The company provided EPS guidance of 8.450-8.850 for the period, compared to the consensus estimate of 8.690. The company also...
MarketBeat·13h ago
News Placeholder
Gilead (GILD) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Gilead (GILD) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks·14h ago
News Placeholder
Gilead Sciences Q4 Earnings Call Highlights
Gilead Sciences (NASDAQ:GILD) executives highlighted what they described as a remarkable year of clinical, commercial, and operational execution in the company's fourth-quarter and full-year 2025...
MarketBeat·14h ago
News Placeholder
Gilead Stock Slips After Q4 Earnings, Weak FY26 Guidance
Here's a look at the details inside Gilead Sciences' fourth-quarter earnings report.read more...
Benzinga·14h ago
News Placeholder
Gilead Sciences Inc. Q4 Profit Advances
(RTTNews) - Gilead Sciences Inc. (GILD) released earnings for its fourth quarter that Increases, from the same period last year...
Nasdaq News: Markets·15h ago
News Placeholder
Gilead Sciences (GILD) Surpasses Q4 Earnings and Revenue Estimates
Gilead (GILD) delivered earnings and revenue surprises of +1.91% and +4.63%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·15h ago
News Placeholder
Gilead Sciences (NASDAQ:GILD) Issues Earnings Results, Misses Estimates By $0.01 EPS
Gilead Sciences (NASDAQ:GILD - Get Free Report) posted its earnings results on Tuesday. The biopharmaceutical company reported $1.86 EPS for the quarter, missing the consensus estimate of $1.87 by...
MarketBeat·16h ago
News Placeholder
Wealthfront Advisers LLC Reduces Holdings in Gilead Sciences, Inc. $GILD
Wealthfront Advisers LLC lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 5.2% in the 3rd quarter, according to the company in its most recent filing with the SEC. The...
MarketBeat·1d ago
<
1
2
...
>

Latest GILD News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.